Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Legend Biotech Corp ADR (NQ: LEGN )

42.43 -0.70 (-1.62%)
Streaming Delayed Price Updated: 12:01 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corp ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Legend Biotech Announces Appointment of Chief Medical Officer
From Legend Biotech
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Legend Biotech Establishes Strategic Advisory Board
From Legend Biotech
Via Business Wire
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
From Legend Biotech
Via Business Wire
Where Legend Biotech Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
4 Analysts Have This to Say About Legend Biotech
Via Benzinga
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
From Legend Biotech
Via Business Wire
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
From Legend Biotech
Via Business Wire
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
From Legend Biotech
Via Business Wire
Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
From Legend Biotech
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
From Legend Biotech Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Carnival, Amazon, Iamgold And Other Big Gainers From Tuesday
U.S. stocks closed higher on Monday, with the Dow Jones gaining more than 300 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday
Gainers COMSovereign Holding Corp. (NASDAQ: COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Monday. 
Via Benzinga
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
From Legend Biotech Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.